The Clinical Applications of Fluorouracil in Ophthalmic Practice

Abraham, Lekha; Selva, Dinesh; Casson, Robert J.; Leibovitch, Igal

doi:10.2165/00003495-200767020-00005

Cited by 117 publications

(149 citation statements)

References 118 publications

Supporting

Mentioning

145

Contrasting

Unclassified

Order By: Relevance

“…As we are interested in drug delivery to the eye, CPT was selected as a model drug because of its rapid cytotoxic profile and the ease with which it can be quantified. It has a similar molecular mass to the DNA cross-linking agent mito mycin C, which is administered topically to the eye after some glaucoma-filtering surgery [77]. Mitomycin C is also cytotoxic for mammalian cells, but is more difficult to quantify accurately than CPT.…”

Section: Resultsmentioning

confidence: 99%

Controlled Drug Delivery From Composites of Nanostructured Porous Silicon and Poly( L -Lactide)

et al. 2012

View full text Add to dashboard Cite

Aims: Porous silicon (pSi) and poly(L-lactide) (PLLA) both display good biocompatibility and tunable degradation behavior, suggesting that composites of both materials are suitable candidates as biomaterials for localized drug delivery into the human body. The combination of a pliable and soft polymeric material with a hard inorganic porous material of high drug loading capacity may engender improved control over degradation and drug release profiles and be beneficial for the preparation of advanced drug delivery devices and biodegradable implants or scaffolds. Materials & methods: In this work, three different pSi and PLLA composite formats were prepared. The first format involved grafting PLLA from pSi films via surface-initiated ring-opening polymerization (pSi–PLLA [grafted]). The second format involved spin coating a PLLA solution onto oxidized pSi films (pSi–PLLA [spin-coated]) and the third format consisted of a melt-cast PLLA monolith containing dispersed pSi microparticles (pSi–PLLA [monoliths]). The surface characterization of these composites was performed via infrared spectroscopy, scanning electron microscopy, atomic force microscopy and water contact angle measurements. The composite materials were loaded with a model cytotoxic drug, camptothecin (CPT). Drug release from the composites was monitored via fluorimetry and the release profiles of CPT showed distinct characteristics for each of the composites studied. Results: In some cases, controlled CPT release was observed for more than 5 days. The PLLA spin coat on pSi and the PLLA monolith containing pSi microparticles both released a CPT payload in accordance with the Higuchi and Ritger–Peppas release models. Composite materials were also brought into contact with human lens epithelial cells to determine the extent of cytotoxicity. Conclusion: We observed that all the CPT containing materials were highly efficient at releasing bioactive CPT, based on the cytotoxicity data. Original submitted 16 December 2010; Revised submitted 29 September 2011; Published online 6 March 2012

show abstract

Section: Resultsmentioning

confidence: 99%

Controlled Drug Delivery From Composites of Nanostructured Porous Silicon and Poly( L -Lactide)

et al. 2012

View full text Add to dashboard Cite

show abstract

“…This practice has been in vogue since 1986. 29 The maximum dosage was 3-5 mg per day, daily for 2 weeks, by subconjunctival injection, amounting to a cumulative maximum dose of 105 mg. 29 In these studies too there was a very low incidence of corneal epitheliopathy. Our adverse events were related to the injection rather than to the drug and included a stinging sensation, despite topical anaesthesia, and subconjunctival haemorrhage.…”

Section: Discussionmentioning

confidence: 99%

Intra-lesional 5 fluorouracil for the management of recurrent pterygium

Said

Faraj

El‐Alfy

et al. 2013

Eye

View full text Add to dashboard Cite

Aim Recurrence is the most common complication arising from pterygium surgery. The aim of this study was to investigate the effectiveness of 5 fluorouracil (5FU) in halting the recurrence of pterygium after surgical excision. Methods A retrospective review of patients treated for pterygium recurrence was carried out. Patients with recurrent (secondary) pterygium were treated with multiple weekly intra-lesional injections of 0.1-0.2 ml (2.5-5 mg) 5FU post-operatively depending on the size of the recurrence. The treatment was started within 1 month from the date of recurrence. The time from surgery to start of recurrence, previous treatment modalities, and number of recurrences were documented. The number of injections required to induce arrest of progression and/ or regression of vascularity and fleshiness of the pterygium and any complications related to 5FU treatment were examined. Results Fifteen eyes from 14 patients with recurrent pterygium treated with intralesional 5FU injections were analysed. Three of the 15 eyes had undergone a secondary excision and 12 had undergone a primary excision. In all, 93.3% of patients showed regression of the fibrovascular tissue (thickness and vascularity) and arrest of progression following a dose of 0.1-0.2 ml (2.5-5 mg) 5FU. Twelve eyes required three injections or fewer, whereas one patient required eight injections. This beneficial effect was maintained over an average follow-up period of 17 months. No complications from 5FU were observed. Conclusion The use of weekly intra-lesional 5FU injections for the treatment of recurrent pterygium is safe and effective in limiting the progression and inducing the regression of recurrent pterygium. The number of injections can be tailored according to clinical need.

show abstract

“…Second, it is a known fact that the use of trabeculectomy without anti-metabolites in adults with glaucoma of African descent is associated with poor outcome, 22,23 a fact that is also demonstrated in adult Ghanaians, 23,24 suggesting a possibility of failure in children of same racial descent. These facts, coupled with the poor result of trabeculectomy in children because of the aggressive wound-healing response, presence of a thick Tenon's capsule and low scleral rigidity, 25 the mild to serious ocular complications that tend to be associated with adjunctive anti-fibrotic drug use, even though the latter on the average improves trabeculectomy outcome, [25][26][27][28][29] all informed our quest to try the CTT alone as an alternate procedure.…”

Section: Eyementioning

confidence: 99%